After gaining key support for Celgene buyout, Bristol-Myers CEO Caforio emerges as likely winner in looming shareholder vote
It’s likely all over but for the shareholder vote and regulatory approvals now.
After Bristol-Myers Squibb’s largest shareholder startled Wall Street with its outright …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.